NONMEM Users Network Archive

Hosted by Cognigen

Seattle Genetics is looking for a Statistical Scientist to join our Translational Medicine Department

From: Tae Han <than>
Date: Mon, 25 Jan 2010 10:01:32 -0800

Statistical Scientist (ID: 42412)
http://ats.staffxl.com/ATS/PortalViewRequirement.do?reqGK=42412

Responsibilities:
- Biostatistical lead for translational medicine, including design of explo=
ratory analyses of biomarkers and predictive/diagnostic assays for phase 1 =
clinical trials
- Work with clinical pharmacology to explore PK/PD relationships
- Work closely with the bioanalytical group in the analysis of novel assays=
 and with research to analyze biomarkers and diagnostic tests during precli=
nical studies of toxicity and efficacy

Requirements:
- Proficiency in biostatistics, programming, and data management required.
- Minimum of 3 years industry experience.
- Preferred skills include PK/PD analysis, experience with genomic analyses=
, development of diagnostics, and prior work in Experimental Medicine/Phase=
 1 programs, especially in oncology indications.
- Excellent interpersonal, presentation, and writing skills desired

About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the d=
evelopment and commercialization of monoclonal antibody-based therapies for=
 the treatment of cancer and autoimmune disease. The company's lead product=
 candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Spe=
cial Protocol Assessment (SPA) with the FDA. Brentuximab vedotin is empower=
ed by Seattle Genetics' proprietary ADC technology comprising highly potent=
 synthetic drugs and stable linkers for attaching the drugs to monoclonal a=
ntibodies. In addition, Seattle Genetics has three other product candidates=
 in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and =
SGN-70. Dacetuzumab is being developed under a worldwide collaboration with=
 Genentech (a wholly-owned member of the Roche Group). Seattle Genetics has=
 collaborations for its ADC technology with a number of leading biotechnolo=
gy and pharmaceutical companies. More information can be found at www.seat=
tlegenetics.com.


Received on Mon Jan 25 2010 - 13:01:32 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com.

Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.